Supply Chain

Federal investigations and public scrutiny over high drug prices won't stop Arthur Bedrosian, CEO of Lannett Co., from raising prices, reports The New York Times.

Low supplies of prescription drugs not only complicate patient care, they also make it more expensive, according to a new study published in the New England Journal of Medicine.

Here are seven articles published by Becker's Hospital Review this week highlighting safety issues with devices, tips for reining in hospital linen costs and supply chain leaders' thoughts on self-distribution, among other topics.

Here are the four latest drugs or medical devices approved by the Food and Drug Administration since March 31.

The Food and Drug Administration on Wednesday sent a warning letter to St. Jude Medical, saying the devicemaker downplayed issues with its defibrillator batteries and failed to recall the devices for years, reports The New York Times.

Neurocrine Bioscience earned Food and Drug Administration approval for its drug Ingrezza.

Smithfield Foods — a major pork producer — created a bioscience unit to focus on supplying pig parts for medical uses. The company's ultimate goal is to sell pig organs for human transplants, reports Reuters.

The U.S. Food and Drug Administration sent a letter to Mylan Pharmaceuticals — the manufacturer of the EpiPen — on April 3 detailing quality control issues at one of the company's facilities in India.

The cost of linen and linen reprocessing can represent 2 to 3 percent of a hospital's total annual budget, and linen is the second largest expense in nursing departments outside of labor, according to Tom Fox, a managing director at…

While a majority of healthcare leaders believe President Donald Trump's administration will take action to lower drug prices, few think these measures will be "meaningful," according to a new survey from Venrock.